



- 1 -

VPI00-115CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,
Serial No.: 09/922,584
Filing Date: August 3, 2001
For: ERK-5 DEFICIENT ANIMALS AND METHODS
OF INHIBITING ANGIOGENESIS THROUGH
THE INHIBITION OF ERK-5

Cambridge, Massachusetts
December 3, 2001

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence
Branch

TRANSMITTAL LETTER FOR CORRECTED FIGURES AND SEQUENCE
LISTING AND DISKETTE


Sir:


Transmitted herewith in response to the Notice
Of Incomplete Nonprovisional Application - Filing Date
Not Granted, mailed October 3, 2001, are the following
materials relating to the above-identified application:

1. Statement under 37 C.F.R. 1.82.1
Certification of Sequence Listing
2. Diskette containing Sequence Listing
and paper copy of sequence list
3. Replacement Figures 1 thru 6
4. Copy of Notice Of Incomplete
Nonprovisional Application - Filing
Date Not Granted;

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,


Andrea L.C. Robidoux (Reg. No. 47,902)
Agent for Applicants
Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6731
Fax.: (617) 444-6483



Certificate Of Mailing Under 37 CFR 1.10

Express Mailing No. ET795387771US Date of Deposit December 3, 2001

I hereby certify that this document/application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202


1. Transmittal of Notice to File Missing Parts
2. Verified Statement under 37 CFR 1.821 (f)
3. Sequence Listing (Paper Copy)
4. Sequence Diskette
5. Replacement Figures 1-6
6. Certificate of Mailing
7. Return Receipt Postcard

Angela J. Billings

(type or printed name of person mailing document/applications)

(signature of person mailing document/application)

VPI/00-115 CIP



- 1 -

VPI00-115 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,
Serial No.: 09/922,584
Filing Date: August 3, 2001
For: ERK-5 DEFICIENT ANIMALS AND METHODS
OF INHIBITING ANGIOGENESIS THROUGH
THE INHIBITION OF ERK-5

Cambridge, Massachusetts
December 3, 2001

Hon. Assistant Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence
Branch

TRANSMITTAL LETTER FOR CORRECTED DRAWINGS AND SEQUENCE
LISTING AND DISKETTE


Sir:

Transmitted herewith in response to the Notice
Of Incomplete Nonprovisional Application - Filing Date
Not Granted, mailed October 3, 2001, are the following
materials relating to the above-identified application:

1. Statement under 37 C.F.R. 1.82.1
Certification of Sequence Listing
2. Diskette containing Sequence Listing
and paper copy of sequence list
3. Corrected Figures 1 thru 6
4. Copy of Notice Of Incomplete
Nonprovisional Application - Filing
Date Not Granted;

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Andréa L.C. Robidoux (Reg. No. 47,902)
Agent for Applicants
Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6731
Fax.: (617) 444-6483